Diligence memo · auto-generated · as of July 2, 2026
Faraday Pharmaceuticals, Inc.
Faraday Pharmaceuticals, Inc. looks fair against its niche peers and is at-risk on financing cadence.
Businessfiled
Faraday Pharmaceuticals, Inc. operates in Pharmaceuticals, based in SEATTLE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Faraday Pharmaceuticals, Inc. has raised $115M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $53M on 2022-10-24.
Most recent recorded round closed around 2022-10-24.
Valuation (modeled)modeled
Provath models Faraday Pharmaceuticals, Inc. at approximately $830M (range $172M–$1.6B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.44× the median modeled value of Series C Pharmaceuticals companies in 2022–2024 (30 peers) — value vs value, same stage and era. Within the normal band (144% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 25 months.
Last raise 3.7 yr ago; this sector typically re-raises about every 13 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round stepped up 2.1× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 92% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 87% of those peers.
Closest niche peers: Vigil Neuroscience, Inc., Leap Therapeutics, Inc., Alimera Sciences Inc, VYNE Therapeutics Inc., Lusaris Therapeutics, Inc..
Peoplefiled
12 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.